This segment focuses on the research, development, manufacturing, and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems, primarily the Eversense and Eversense XL products. Research and development activities include sensor technology advancements, improved accuracy, and extended sensor life. Technologies used encompass implantable sensors, smart transmitters, and mobile applications for real-time glucose monitoring. The therapeutic area is diabetes, specifically targeting individuals requiring continuous glucose monitoring for effective diabetes management. Patient impact is significant, offering improved glycemic control, reduced risk of hypoglycemia, and enhanced quality of life. Market positioning is centered on providing a unique, long-term CGM solution, differentiating from short-term CGM options. Future opportunities include expanding product offerings, geographic expansion, and integration with other diabetes management tools. Regulatory and clinical aspects involve FDA approvals and ongoing clinical trials to demonstrate safety and efficacy. Partnerships with healthcare providers, distributors, and strategic fulfillment partners are crucial for market access and patient support.